KRAS and pancreatic neoplasm: Pancreatic cancer patients with KRAS at codon 61 mutations exhibit lower extracellular signal-regulated kinase (ERK) activation compared with patients with other KRAS alleles, and the former harbor significantly better prognosis.19–21 It is evident that KRAS mutation seems to be necessary but not sufficient for pancreatic cancer development.